Unassociated Document
Filed
Pursuant to Rule 424(b)(3)
Registration
No. 333-151973
PROSPECTUS
$30,000,000
HUDSON
TECHNOLOGIES, INC.
Common
Stock
|
Preferred
Stock |
Warrants |
Debt
Securities |
From
time
to time, we may offer and sell common stock, preferred stock, warrants or debt
securities or any combination of securities described in this prospectus, either
individually, or in units, at prices and on terms described in one or more
supplements to this prospectus. The aggregate public offering price of the
securities offered by this prospectus will not exceed $30 million.
This
prospectus provides you with a general description of the securities that we
may
offer in one or more offerings. Each time we offer securities, we will provide
a
supplement to this prospectus that will contain more specific information about
the terms of that offering. We may also add, update or change in the prospectus
supplement any of the information contained in this prospectus.
You
should read both this prospectus and the applicable prospectus supplement,
as
well as any documents incorporated by reference in this prospectus and/or the
applicable prospectus supplement, before you make your investment
decision.
Our
common stock is traded on the Nasdaq Capital Market under the trading symbol
“HDSN.” On September 4, 2008, the last reported sale price of our common stock
on the Nasdaq Capital Market was $2.23 per share.
Investing
in our securities involves risks. See the risks and uncertainties described
under the heading “Risk Factors” contained in any applicable prospectus
supplement and under similar headings in the other documents that are
incorporated by reference into this prospectus.
This
prospectus may not be used to sell any of our securities unless accompanied
by a
prospectus supplement.
The
securities offered by this prospectus may be sold directly by us to investors,
through agents designated from time to time or to or through one or more
underwriters or dealers or in other manners as set forth under the heading
“Plan
of Distribution.” In addition, each time we offer securities, the supplement to
this prospectus applicable to such offering will provide the specific terms
of
the plan of distribution for such offering and the net proceeds that we expect
to receive from such offering.
The
aggregate market value of our outstanding common stock held by non-affiliates
is
$23,448,568 based on 19,416,187 shares of outstanding common stock, of which
10,515,053 are held by non-affiliates, and a per share price of $2.23 based
on
the closing sale price of our common stock on September 4, 2008. We have not
offered any securities during the past twelve months pursuant to General
Instruction I.B.6. of Form S-3.
Neither
the Securities and Exchange Commission nor any state securities commission
has
approved or disapproved of these securities or determined if this prospectus
is
truthful or complete. Any representation to the contrary is a criminal
offense.
The
date
of this prospectus is September 5, 2008.
|
|
|
Page |
|
|
|
|
|
|
SUMMARY
|
|
|
1
|
|
|
|
|
|
|
|
|
|
2
|
|
|
|
|
|
|
ABOUT
THIS PROSPECTUS
|
|
|
2
|
|
|
|
|
|
|
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
|
|
2
|
|
|
|
|
|
|
USE
OF PROCEEDS
|
|
|
2
|
|
|
|
|
|
|
DESCRIPTION
OF COMMON STOCK
|
|
|
2
|
|
|
|
|
|
|
DESCRIPTION
OF PREFERRED STOCK
|
|
|
3
|
|
|
|
|
|
|
DESCRIPTION
OF WARRANTS
|
|
|
6
|
|
|
|
|
|
|
DESCRIPTION
OF DEBT SECURITIES
|
|
|
7
|
|
|
|
|
|
|
PLAN
OF DISTRIBUTION
|
|
|
14
|
|
|
|
|
|
|
LEGAL
MATTERS
|
|
|
15
|
|
|
|
|
|
|
EXPERTS
|
|
|
15
|
|
|
|
|
|
|
WHERE
YOU CAN FIND MORE INFORMATION
|
|
|
15
|
|
|
|
|
|
|
INFORMATION
INCORPORATED BY REFERENCE
|
|
|
16
|
|
SUMMARY
About
Hudson Technologies, Inc.
We
are a
refrigerant services company providing innovative solutions to recurring
problems within the refrigeration industry. Our products and services are
primarily used in commercial air conditioning, industrial processing and
refrigeration systems, including (i) refrigerant sales, (ii) refrigerant
management services consisting primarily of reclamation of refrigerants and
(iii) RefrigerantSide® Services performed at a customer's site, consisting of
system decontamination to remove moisture, oils and other contaminants. In
addition, RefrigerantSide® Services include predictive and diagnostic services
for industrial and commercial refrigeration applications designed to predict
potential catastrophic problems and identify inefficiencies in an operating
system. Our Chiller Chemistry®, Chill Smart®, Fluid Chemistry, and Performance
Optimization are predictive and diagnostic service offerings. We operate through
our wholly-owned subsidiary, Hudson Technologies Company. Unless the context
requires otherwise, references to the "Company", "Hudson", "we", "us", "our",
or
similar pronouns refer to Hudson Technologies, Inc. and its
subsidiaries.
We
are
incorporated under the laws of the State of New York. Our
executive offices are located at One Blue Hill Plaza, Pearl River, New York
and
our telephone number is (845) 735-6000.
Our
web
site address is www.hudsontech.com.
We have
included our web site address in this document as an inactive textual reference
only, and the information contained in, or that can be accessed through, our
web
site does not constitute part of this prospectus.
RISK
FACTORS
Any
investment in our securities involves a high degree of risk. You should consider
carefully the risk factors described in our periodic reports filed with the
SEC
(including the risks, uncertainties and assumptions discussed under the heading
“Risk Factors” included in our most recent annual report on Form 10-KSB or 10-K,
as the case may be, as such may be revised or supplemented prior to the
completion of this offering by more recently filed quarterly reports on Form
10-Q, each of which is or upon filing will be incorporated herein by reference),
which may be amended, supplemented or superseded from time to time by other
reports we file with the SEC in the future, and those identified in any
applicable prospectus supplement, as well as other information in this
prospectus and any applicable prospectus supplement and the documents
incorporated by reference herein before purchasing any of our securities. Each
of these risk factors could adversely affect our business, operating results
and
financial condition, as well as adversely affect the value of an investment
in
our securities.
ABOUT
THIS PROSPECTUS
You
should rely only on the information provided in or incorporated by reference
in
this prospectus, any prospectus supplement or documents to which we otherwise
refer you. We have not authorized anyone else to provide you with different
information. We are not making an offer of any securities in any jurisdiction
where the offer is not permitted, and this document may only be used where
it is
legal to sell the securities described herein. You should not assume that
the
information in this prospectus, any prospectus supplement or any document
incorporated by reference is accurate as of any date other than the date
of the
document in which such information is contained or such other date referred
to
in such document, regardless of the time of any sale or issuance of the
securities.
This
prospectus is part of a registration statement that we filed with the Securities
and Exchange Commission, or SEC, to register an indeterminable number of
shares
of common stock, preferred stock, warrants and debt securities as may from
time
to time be offered for sale, either individually or in units, at indeterminate
prices (up to an aggregate maximum offering price for all such securities
of $30
million), using a “shelf” registration process. By using a shelf registration
statement, we may offer and sell from time to time in one or more offerings
the
securities described in this prospectus.
This
prospectus provides you with some of the general terms that may apply to
an
offering of our securities. Each time we sell securities under this shelf
registration we will provide a prospectus supplement that will contain
specific
information about the terms of that specific offering, including the number
and
price per security (or exercise price) of the securities to be offered
and sold
in that offering and the specific manner in which such securities may be
offered. The prospectus supplement may also add to, update or change any
of the
information contained in this prospectus. If there is an inconsistency
between
the information in this prospectus and a prospectus supplement, you should
rely
on the information in the prospectus supplement.
You
should read carefully both this prospectus and the applicable prospectus
supplement, together with the additional information incorporated by reference
herein as described under the heading “Information Incorporated by Reference,”
before making an investment decision.
The
registration statement that contains this prospectus (including the exhibits
to
the registration statement) contains additional information about us and
the
securities offered under this prospectus. That registration statement can
be
read at the SEC web site (www.sec.gov)
or at
the SEC offices mentioned under the heading “Where You Can Find More
Information.”
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus and the documents incorporated by reference herein contain statements
that we believe are “forward-looking statements” as that term is used in the
Private Securities Litigation Reform Act of 1995 and are intended to enjoy
protection of the safe harbor for forward-looking statements provided by that
Act. These forward-looking statements are based on our current expectations,
assumptions, estimates and projections about our business and our industry.
Forward-looking statements include statements regarding our future financial
position, performance and achievements, business strategy, and plans and
objectives of management for future operations.
In
some
cases, you can identify forward-looking statements by terms such as “may,”
“should,” “will,” “could,” “estimate,” “project,” “predict,” “potential,”
“continue,” “anticipate,” “believe,” “plan,” “seek,” “expect,” “future” and
“intend” or the negative of these terms or other comparable expressions which
are intended to identify forward-looking statements. These statements are only
predictions and are not guarantees of future performance. They are subject
to
known and unknown risks, uncertainties and other factors, some of which are
beyond our control and difficult to predict and could cause our actual results
to differ materially from those expressed or forecasted in, or implied by,
the
forward-looking statements. In evaluating these forward-looking statements,
you
should carefully consider the risks and uncertainties referred to under the
caption “Risk Factors” above and elsewhere in this prospectus, including those
described in documents incorporated by reference herein, and those described
in
any applicable prospectus supplement. Given these uncertainties, you should
not
place undue reliance on these forward-looking statements. In addition, these
forward-looking statements reflect our view only as of the date they are
made.
Except
as
required by law, we assume no obligation to update these forward-looking
statements publicly, or to update the reasons actual results could differ
materially from those anticipated in these forward-looking statements, even
if
new information becomes available in the future.
All
forward-looking statements attributable to us or persons acting on our behalf
are expressly qualified in their entirety by these cautionary
statements.
USE
OF PROCEEDS
Except
as
may be described otherwise in a prospectus supplement, we will add the net
proceeds from the sale of securities under this prospectus to our general funds
and will use them for working capital and/or general corporate purposes
and/or acquisitions.
Pending
the application of such proceeds, we expect to invest the proceeds in
short-term, interest bearing, investment-grade marketable securities or money
market obligations.
DESCRIPTION
OF COMMON STOCK
Hudson
is
authorized to issue 50,000,000 shares of common stock. As of September 4, 2008,
there were 19,416,187 shares of common stock outstanding.
The
holders of common stock are entitled to one vote for each share held of record
on all matters to be voted on by stockholders. There is no cumulative voting
with respect to the election of directors, with the result that the holders
of
more than 50% of the shares voting for the election of directors can elect
all
of the directors then up for election. The holders of common stock are entitled
to receive dividends when, as and if declared by our Board of Directors out
of
funds legally available therefor. In the event of liquidation, dissolution
or
winding up of Hudson, the holders of common stock are entitled to share in
all
assets remaining which are available for distribution to them after payment
of
liabilities and after provision has been made for each class of stock, if any,
having preference over the common stock. Holders of shares of common stock
have
no conversion, preemptive or other subscription rights, and there are no
redemption provisions applicable to the common stock. All of the outstanding
shares of common stock are fully paid and nonassessable.
Transfer
Agent
The
transfer agent and registrar for the common stock is Continental Stock Transfer
& Trust Company, New York, New York.
Anti-Takeover
Effects of Provisions of Our Bylaws
Our
By-laws provide that our Board of Directors is divided into two classes. Each
class is to have a term of two years, with the term of each class expiring
in
successive years, and is to consist, as nearly as possible, of one-half of
the
number of directors constituting the entire Board. Under certain circumstances,
at least two annual meetings of stockholders, instead of one, may be required
to
effect a change in a majority of our board of directors. The classification
of
our board into two separate classes, could discourage, delay, or prevent a
takeover of us thereby preserving control by the current
stockholders.
DESCRIPTION
OF PREFERRED STOCK
Hudson
is
authorized to issue 5,000,000 shares of preferred stock. As of September 4,
2008, there were 150,000 shares of preferred stock designated as Series A
Convertible Preferred Stock and no shares of preferred stock outstanding. Hudson
has no intent to issue any shares of its Series A Convertible Preferred Stock.
This
section describes the general terms of our preferred stock to which any
prospectus supplement may relate. A prospectus supplement will describe the
terms relating to any preferred stock to be offered by us in greater detail,
and
may provide information that is different from this prospectus. If the
information in the prospectus supplement with respect to the particular
preferred stock being offered differs from this prospectus, you should rely
on
the information in the prospectus supplement. A copy of our certificate of
incorporation, as amended, has been incorporated by reference from our filings
with the SEC as an exhibit to the registration statement. A certificate of
amendment to our certificate of incorporation will specify the terms of the
preferred stock being offered, and will be filed or incorporated by reference
from a report that we file with the SEC.
Under
our
certificate of incorporation, as amended, we have the authority to issue
5,000,000 shares of preferred stock. The authorized preferred stock can be
issued from time to time in one or more series. Our Board of Directors has
the
power, without stockholder approval, to issue shares of one or more series
of
preferred stock, at any time, for such consideration and with such relative
rights, privileges, preferences and other terms as the Board may determine,
including terms relating to dividend rates, redemption rates, liquidation
preferences and voting, sinking fund and conversion or other rights. The rights
and terms relating to any new series of preferred stock could adversely affect
the voting power or other rights of the holders of the common stock or could
be
utilized, under certain circumstances, as a method of discouraging, delaying
or
preventing a change in control of Hudson.
The
following description of our preferred stock, together with any
description of our preferred stock in a prospectus supplement summarizes the
material terms and provisions of the preferred stock that we may sell under
this
prospectus. We urge you to read the applicable prospectus supplement(s) related
to the particular series of preferred stock that we sell under this prospectus
and to the actual terms and provisions contained in our certificate of
incorporation and bylaws, each as amended from time to time.
Terms
Our
board
of directors will fix the rights, preferences, privileges, qualifications and
restrictions of the preferred stock of each series that we sell under this
prospectus and applicable prospectus supplements in the amendment to our
certificate of incorporation relating to that series. We will incorporate
by reference into the registration statement of which this prospectus is a
part
the form of any amendment to our certificate of incorporation that describes
the
terms of the series of preferred stock we are offering before the issuance
of
the related series of preferred stock. This description of the preferred
stock in the amendment to our certificate of incorporation and any
applicable prospectus supplement may include:
|
•
|
|
the
number of shares of preferred stock to be issued and the offering
price of
the preferred stock;
|
|
|
|
|
|
•
|
|
the
title and stated value of the preferred stock;
|
|
|
|
|
|
•
|
|
dividend
rights, including dividend rates, periods, or payment dates, or methods
of
calculation of dividends applicable to the preferred
stock;
|
|
|
|
|
|
•
|
|
whether
dividends will be cumulative or non-cumulative, and if
cumulative
the date from which distributions on the preferred stock shall
accumulate;
|
|
|
|
|
|
•
|
|
right
to convert the preferred stock into a different type of
security;
|
|
•
|
|
voting
rights, if any, attributable to the preferred stock;
|
|
|
|
|
|
•
|
|
rights
and preferences upon our liquidation or winding up of our
affairs;
|
|
|
|
|
|
•
|
|
terms
of redemption;
|
|
|
|
|
|
•
|
|
preemption
rights, if any;
|
|
|
|
|
|
•
|
|
the
procedures for any auction and remarketing, if any, for the preferred
stock;
|
|
|
|
|
|
•
|
|
the
provisions for a sinking fund, if any, for the preferred
stock;
|
|
|
|
|
|
•
|
|
any
listing of the preferred stock on any securities
exchange;
|
|
|
|
|
|
•
|
|
the
terms and conditions, if applicable, upon which the preferred stock
will
be convertible into our common stock, including the conversion price
(or
manner of calculation thereof);
|
|
|
|
|
|
•
|
|
a
discussion of federal income tax considerations applicable to the
preferred stock, if material;
|
|
|
|
|
|
•
|
|
the
relative ranking and preferences of the preferred stock as to dividend
or
other distribution rights and rights if we liquidate, dissolve or
wind up
our affairs;
|
|
|
|
|
|
•
|
|
any
limitations on issuance of any series of preferred stock ranking
senior to
or on a parity with the series of preferred stock being offered as
to
distribution rights and rights upon the liquidation, dissolution
or
winding up or our affairs; and
|
|
|
|
|
|
•
|
|
any
other specific terms, preferences, rights, limitations or restrictions
of
the preferred stock.
|
Rank
Unless
otherwise indicated in the applicable supplement to this prospectus, shares
of
our preferred stock will rank, with respect to payment of distributions and
rights upon our liquidation, dissolution or winding up, and allocation of our
earnings and losses:
|
•
|
|
senior
to all classes or series of our common stock, and to all of our equity
securities ranking junior to the preferred stock;
|
|
|
|
|
|
•
|
|
on
a parity with all equity securities issued by us, the terms of which
specifically provide that these equity securities rank on a parity
with
the preferred stock; and
|
|
|
|
|
|
•
|
|
junior
to all equity securities issued by us, the terms of which specifically
provide that these equity securities rank senior to the preferred
stock.
|
Distributions
Subject
to any preferential rights of any outstanding stock or series of stock, our
preferred shareholders are entitled to receive distributions, when and as
authorized by our board of directors, out of legally available funds, and share
pro rata based on the number of shares of preferred stock, common stock and
other equity securities outstanding.
Voting
Rights
Unless
otherwise indicated in the applicable supplement to this prospectus, or
otherwise required under New York law, holders of our preferred stock will
not
have any voting rights.
Liquidation
Preference
Upon
the
voluntary or involuntary liquidation, dissolution or winding up of our affairs,
then, before any distribution or payment shall be made to the holders of any
common stock or any other class or series of stock ranking junior to the
preferred stock in our distribution of assets upon any liquidation, dissolution
or winding up, the holders of each series of our preferred stock are entitled
to
receive, after payment or provision for payment of our debts and other
liabilities, out of our assets legally available for distribution to
shareholders, liquidating distributions in the amount of the liquidation
preference per share (set forth in the applicable supplement to this
prospectus), plus an amount, if applicable, equal to all distributions accrued
and unpaid thereon (which shall not include any accumulation in respect of
unpaid distributions for prior distribution periods if the preferred stock
does
not have a cumulative distribution). After payment of the full amount of the
liquidating distributions to which they are entitled, the holders of preferred
stock will have no right or claim to any of our remaining assets. In the event
that, upon our voluntary or involuntary liquidation, dissolution or winding
up,
the legally available assets are insufficient to pay the amount of the
liquidating distributions on all of our outstanding preferred stock and the
corresponding amounts payable on all of our stock of other classes or series
of
equity security ranking on a parity with the preferred stock in the distribution
of assets upon liquidation, dissolution or winding up, then the holders of
our
preferred stock and all other such classes or series of equity securities will
share ratably in the distribution of assets in proportion to the full
liquidating distributions to which they would otherwise be respectively
entitled.
If
the
liquidating distributions are made in full to all holders of preferred stock,
our remaining assets will be distributed among the holders of any other classes
or series of equity security ranking junior to the preferred stock upon our
liquidation, dissolution, or winding up, according to their respective rights
and preferences and in each case according to their respective number of shares
of stock.
Conversion
Rights
The
terms
and conditions, if any, upon which shares of any series of preferred stock
are
convertible into, such as common stock, debt securities, warrants or units
consisting of one or more of such securities will be set forth in the applicable
supplement to this prospectus. These terms will include the amount and type
of
security into which the shares of preferred stock are convertible, the
conversion price (or manner of calculation thereof), the conversion period,
provisions as to whether conversion will be at the option of the holders of
the
preferred stock or us, the events, if any, requiring an adjustment of the
conversion price and provisions, if any, affecting conversion in the event
of
the redemption of that preferred stock.
Redemption
If
so
provided in the applicable supplement to this prospectus, our preferred stock
will be subject to mandatory redemption or redemption at our option, in whole
or
in part, in each case upon the terms, at the times and at the redemption prices
set forth in such supplement to this prospectus.
The
following description, together with the additional information we may include
in any applicable prospectus supplements, summarizes the material terms and
provisions of the warrants that we may offer under this prospectus. While the
terms we have summarized below will apply generally to any warrants that we
may
offer under this prospectus, we will describe the particular terms of any series
of warrants in more detail in the applicable prospectus supplement. The terms
of
any warrants offered under a prospectus supplement may differ from the terms
described below.
We
will
file as exhibits to the registration statement of which this prospectus is
a
part, or will incorporate by reference from another report that we file with
the
SEC, the form of warrant agreement, which may include a form of warrant
certificate, that describes the terms of the particular series of warrants
we
are offering before the issuance of the related series of warrants. The
following summary of material provisions of the warrants and the warrant
agreements are subject to all the provisions of the warrant agreement and
warrant certificate applicable to a particular series of warrants. We urge
you
to read the applicable prospectus supplements related to the particular series
of warrants that we sell under this prospectus, as well as the complete warrant
agreements and warrant certificates that contain the terms of the
warrants.
General
We
will
describe in the applicable prospectus supplement the terms relating to warrants
being offered including:
|
·
|
the
offering price and aggregate number of warrants
offered;
|
|
|
|
|
·
|
if
applicable, the designation and terms of the securities with which
the
warrants are issued and the number of warrants issued with each such
security or each principal amount of such security;
|
|
|
|
|
·
|
if
applicable, the date on and after which the warrants and the related
securities will be separately transferable;
|
|
|
|
|
·
|
in
the case of warrants to purchase common stock or preferred stock,
the
number of shares of common stock or preferred stock, as the case
may be,
purchasable upon the exercise of one warrant and the price at which
these
shares may be purchased upon such exercise;
|
|
|
|
|
·
|
the
terms of any rights to redeem or call the warrants;
|
|
|
|
|
·
|
any
provisions for changes to or adjustments in the exercise price or
number
of securities issuable upon exercise of the warrants;
|
|
|
|
|
·
|
the
dates on which the right to exercise the warrants will commence and
expire;
|
|
|
|
|
·
|
the
manner in which the warrant agreements and warrants may be
modified;
|
|
|
|
|
·
|
federal
income tax consequences of holding or exercising the warrants, if
material;
|
|
|
|
|
·
|
the
terms of the securities issuable upon exercise of the warrants;
and
|
|
|
|
|
·
|
any
other specific terms, preferences, rights or limitations of or
restrictions on the warrants.
|
Before
exercising their warrants, holders of warrants will not have any of the rights
of holders of the securities purchasable upon such exercise, including, in
the
case of warrants to purchase common stock or preferred stock, the right to
receive dividends, if any, or payments upon our liquidation, dissolution or
winding up of our affairs or to exercise voting rights, if any.
Exercise
of Warrants
Each
warrant will entitle the holder to purchase the securities that we specify
in
the applicable prospectus supplement at the exercise price that we describe
in
the applicable prospectus supplement. Unless we otherwise specify in the
applicable prospectus supplement, holders of the warrants may exercise the
warrants at any time up to the specified time on the expiration date that we
set
forth in the applicable prospectus supplement. After the close of business
on
the expiration date, unexercised warrants will become void.
Holders
of the warrants may exercise the warrants by delivering the warrant certificate
representing the warrants to be exercised together with specified information,
and paying the required amount to the warrant agent in immediately available
funds, as provided in the applicable prospectus supplement. We intend to set
forth in any warrant agreement and in the applicable prospectus supplement
the
information that the holder of the warrant will be required to deliver to the
warrant agent.
Upon
receipt of the required payment and any warrant certificate or other form
required for exercise properly completed and duly executed at the corporate
trust office of the warrant agent or any other office indicated in the
applicable prospectus supplement, we will issue and deliver the securities
purchasable upon such exercise. If fewer than all of the warrants represented
by
the warrant or warrant certificate are exercised, then we will issue a new
warrant or warrant certificate for the remaining amount of warrants. If we
so
indicate in the applicable prospectus supplement, holders of the warrants may
surrender securities as all or part of the exercise price for
warrants.
We
may
issue debt securities, in one or more series, which may be senior or convertible
debt. While the terms we have summarized below we expect will apply generally
to
any debt securities that we may offer under this prospectus, we will describe
the particular terms of any debt securities that we may offer in more detail
in
the applicable prospectus supplement. The terms of any debt securities offered
under a prospectus supplement may differ from the terms described below. We
will
file as exhibits to the registration statement of which this prospectus is
a
part, or will incorporate by reference from reports that we file with the SEC,
forms of debt securities and/or any indentures containing the terms of the
debt
securities being offered. Any debt securities which we offer by this prospectus
will be exempt under the Trust Indenture Act of 1939, as amended (the “Trust
Indenture Act”). Therefore, we may not use an indenture (and, thus a trustee)
or, if we use an indenture, it may not fully comply with the requirements of
the
Trust Indenture Act.
The
documentation governing the debt securities may provide for an agent to act
for
and on behalf of the holders of the debt securities. We will file as exhibits
to
the registration statement of which this prospectus is a part, or will
incorporate by reference from reports that we file with the SEC, supplemental
forms of debt securities and/or indentures containing the terms of the debt
securities being offered.
The
following summaries of material provisions of the debt securities we may issue
are subject to, and qualified in their entirety by reference to, all of the
provisions of the documentation applicable to a particular series of debt
securities. We urge you to read the applicable prospectus supplements that
we
may offer under this prospectus.
General
We
will
describe in the applicable prospectus supplement the terms of the debt
securities being offered, including:
·
|
the
principal amount being offered, and if a series, the total amount
authorized and the total amount
outstanding;
|
·
|
any
limit on the amount that may be
issued;
|
·
|
whether
or not we will issue the series of debt securities in global form,
the
terms and who the depositary will
be;
|
·
|
the
terms of the conversion rights;
|
·
|
the
annual interest rate, which may be fixed or variable, or the method
for
determining the rate and the date interest will begin to accrue,
the dates
interest will be payable and the regular record dates for interest
payment
dates or the method for determining such
dates;
|
·
|
whether
or not the debt securities will be secured or unsecured, and the
terms of
any secured debt;
|
·
|
the
terms of the subordination of any series of subordinated
debt;
|
·
|
the
place where payments will be
payable;
|
·
|
if
payment of principal and interest on the debt securities may be paid
in
our securities rather than, or in addition to cash, and the terms
of any
such rights;
|
·
|
restrictions
on transfer, sale or other assignment, if
any;
|
·
|
our
right, if any, to defer payment of interest and the maximum length
of any
such deferral period;
|
·
|
the
date, if any, after which, and the price at which, we may, at our
option,
redeem the series of debt securities pursuant to any optional or
provisional redemption provisions and the terms of those redemption
provisions;
|
·
|
the
date, if any, on which, and the price at which we are obligated,
pursuant
to any mandatory sinking fund or analogous fund provisions or otherwise,
to redeem, or at the holder’s option to purchase, the series of debt
securities and the currency or currency unit in which the debt securities
are payable;
|
·
|
whether
the debt securities will restrict our ability and/or the ability
of our
subsidiaries to:
|
·
|
incur
additional indebtedness;
|
·
|
issue
additional securities;
|
·
|
pay
dividends and make distributions in respect of our capital stock
and the
capital stock of our subsidiaries;
|
·
|
place
restrictions on our subsidiaries’ ability to pay dividends, make
distributions or transfer assets;
|
·
|
make
investments or other restricted
payments;
|
·
|
sell
or otherwise dispose of assets;
|
·
|
enter
into sale-leaseback transactions;
|
·
|
engage
in transactions with shareholders and
affiliates;
|
·
|
issue
or sell stock of our subsidiaries;
or
|
·
|
effect
a consolidation or merger;
|
·
|
whether
the debt securities will require us to maintain any interest coverage,
fixed charge, cash flow-based, asset-based or other financial
ratios;
|
·
|
a
discussion of any material United States federal income tax considerations
applicable to the debt securities;
|
·
|
information
describing any book-entry features;
|
·
|
provisions
for a sinking fund purchase or other analogous fund, if
any;
|
·
|
the
applicability of the provisions in the debt securities on
discharge;
|
·
|
the
denominations in which we will issue the series of debt securities,
if
other than denominations of $1,000 and any integral multiple
thereof;
|
·
|
the
currency of payment of debt securities if other than U.S. dollars
and the
manner of determining the equivalent amount in U.S. dollars;
and
|
·
|
any
other specific terms, preferences, rights or limitations of, or
restrictions on, the debt securities, including any events of default
or
covenants provided with respect to the debt securities, and any terms
that
may be required by us or advisable under applicable laws or
regulations.
|
Conversion
or Exchange Rights
We
will
set forth in the prospectus supplement the terms on which a series of debt
securities may be convertible into or exchangeable for our common stock,
preferred stock, other debt securities, warrants or units consisting of one
or
more of such securities. We will include provisions as to whether conversion
or
exchange is mandatory, at the option of the holder or at our option. We may
include provisions pursuant to which the number of shares of our common stock,
preferred stock, other debt securities, warrants or units consisting of one
or
more of such securities, that the holders of the series of debt securities
receive would be subject to adjustment.
Consolidation,
Merger or Sale
We
do not
currently expect our debt securities to contain any covenant that restricts
our
ability to merge or consolidate, or sell, convey, transfer or otherwise dispose
of all or substantially all (i.e. more than 75%) of our assets. However, any
successor to or acquirer of such assets may be required to assume all of our
obligations under the debt securities, as appropriate. If the debt securities
are convertible into or exchangeable for our other securities or securities
of
other entities, the person with whom we consolidate or merge or to whom we
sell
all or substantially all of our assets may be required to make provisions for
the conversion of the debt securities into securities that the holders of the
debt securities would have received if they had converted the debt securities
before the consolidation, merger or sale.
Events
of Default Under the Debt Securities
Unless
we
provide otherwise in the prospectus supplement applicable to a particular series
of debt securities or the debt agreement or indenture governing the debt
securities, the following are events of default with respect to any series
of
debt securities that we may issue:
·
|
if
we fail to pay interest when due and payable and our failure continues
for
90 days and the time for payment has not been extended or
deferred;
|
·
|
if
we fail to pay the principal, premium or sinking fund payment, if
any,
when due and payable and the time for payment has not been extended
or
delayed;
|
·
|
if
we fail to observe or perform any other covenant contained in the
debt
securities, other than a covenant specifically relating to another
series
of debt securities, and our failure continues for 90 days after we
receive
notice from the debt securities agent or holders of at least 25%
in
aggregate principal amount of the outstanding debt securities of
the
applicable series;
|
·
|
if
specified events of bankruptcy, insolvency or reorganization occur;
and
|
·
|
any
other event of default provided in or pursuant to the applicable
agreement
or indenture, if any, or prospectus supplement with respect to the
debt
securities of that series.
|
The
holders of a majority in principal amount of the outstanding debt securities
of
an affected series may waive any default or event of default with respect to
the
series and its consequences, except defaults or events of default regarding
payment of principal, premium, if any, or interest, unless we have cured the
default or event of default in accordance with the form of debt security and/or
agreement or indenture. Any waiver shall cure the default or event of
default.
The
holders of a majority in principal amount of the outstanding debt securities
of
any series will have the right to direct the time, method and place of
conducting any proceeding for any remedy available to such holders with respect
to the debt securities of that series.
Subject
to the terms of the debt securities, if an event of default thereunder shall
occur and be continuing, the debt securities agent will be under no obligation
to exercise any of its rights or powers under such debt securities at the
request or direction of any of the holders of the applicable series of debt
securities, unless such holders have offered the debt securities agent
reasonable indemnity. The holders of a majority in principal amount of the
outstanding debt securities of any series will have the right to direct the
time, method and place of conducting any proceeding for any remedy available
to
the debt securities agent, or exercising any trust or power conferred on the
debt securities agent, with respect to the debt securities of that series,
provided that:
·
|
the
direction so given by the holder is not in conflict with any law
or the
applicable debt securities; and
|
·
|
the
debt securities agent need not take any action that might involve
it in
personal liability or might be unduly prejudicial to the holders
not
involved in the proceeding.
|
A
holder
of the debt securities of any series will have the right to institute a
proceeding under the debt securities or to appoint a receiver or trustee, or
to
seek other remedies only if:
·
|
the
holder has given written notice to the debt securities agent of a
continuing event of default with respect to that
series;
|
·
|
the
holders of at least 25% in aggregate principal amount of the outstanding
debt securities of that series have made written request, and such
holders
have offered reasonable indemnity to the debt securities agent to
institute the proceeding as trustee;
and
|
·
|
the
debt securities agent does not institute the proceeding, and does
not
receive from the holders of a majority in aggregate principal amount
of
the outstanding debt securities of that series other conflicting
directions within 90 days after the notice, request and
offer.
|
These
limitations do not apply to a suit instituted by a holder of debt securities
if
we default in the payment of the principal, premium, if any, or interest on,
the
debt securities.
We
may
periodically file statements with the debt securities agent regarding our
compliance with specified covenants in the documentation regarding such debt
securities.
Modification;
Waiver
We
and
the debt securities agent may change the form of debt security and/or indenture
without the consent of any holders with respect to specific
matters:
·
|
to
fix any ambiguity, defect or inconsistency in the documentation governing
the debt securities;
|
·
|
to
comply with the provisions described above under “Description of Debt
Securities — Consolidation, Merger or
Sale;”
|
·
|
to
add to, delete from or revise the conditions, limitations, and
restrictions on the authorized amount, terms, or purposes of issue,
authentication and delivery of debt securities, as set forth in the
documentation governing such debt
securities;
|
·
|
to
provide for the issuance of and establish the form and terms and
conditions of the debt securities of any series as provided under
“Description of Debt Securities — General” to establish the form of any
certifications required to be furnished pursuant to the terms of
any
series of debt securities, or to add to the rights of the holders
of any
series of debt securities;
|
·
|
to
evidence and provide for the acceptance of appointment thereunder
by a
successor debt securities agent;
|
·
|
to
provide for uncertificated debt securities in addition to or in place
of
certificated debt securities and to make all appropriate changes
for such
purpose;
|
·
|
to
add to our covenants new covenants, restrictions, conditions or provisions
for the protection of the holders, and to make the occurrence, or
the
occurrence and the continuance, of a default in any such additional
covenants, restrictions, conditions or provisions an event of default;
or
|
·
|
to
change anything that does not materially adversely affect the interests
of
any holder of debt securities of any
series.
|
In
addition, the rights of holders of a series of debt securities may be changed
by
us and the debt securities agent with the written consent of the holders of
at
least a majority in aggregate principal amount of the outstanding debt
securities of each series that is affected. However, unless we provide otherwise
in the prospectus supplement applicable to a particular series of debt
securities, we and the debt securities agent may make the following changes
only
with the consent of each holder of any outstanding debt securities
affected:
·
|
extending
the fixed maturity of the series of debt
securities;
|
·
|
reducing
the principal amount, reducing the rate of or extending the time
of
payment of interest, or reducing any premium payable upon the redemption
of any debt securities; or
|
·
|
reducing
the percentage of debt securities, the holders of which are required
to
consent to any amendment, supplement, modification or
waiver.
|
Discharge
The
documentation governing the debt securities may provide that we can elect to
be
discharged from our obligations with respect to one or more series of debt
securities, except for specified obligations, including obligations
to:
·
|
register
the transfer or exchange of debt securities of the
series;
|
·
|
replace
stolen, lost or mutilated debt securities of the
series;
|
·
|
maintain
paying agencies;
|
·
|
hold
monies for payment in trust;
|
·
|
recover
excess money held by the debt securities
agent;
|
·
|
indemnify
the debt securities agent; and
|
·
|
appoint
any successor debt securities
agent.
|
In
order
to exercise our rights to be discharged, we must deposit with the debt
securities agent money or government obligations sufficient to pay all the
principal of, any premium, if any, and interest on, the debt securities of
the
series on the dates payments are due.
Form,
Exchange and Transfer
We
will
issue the debt securities of each series only in fully registered form without
coupons and, unless we provide otherwise in the applicable prospectus
supplement, in denominations of $1,000 and any integral multiple
thereof.
At
the
option of the holder, subject to the terms of the debt securities set forth
in
the applicable prospectus supplement, the holder of the debt securities of
any
series can exchange the debt securities for other debt securities of the same
series, in any authorized denomination and of like tenor and aggregate principal
amount.
Subject
to the terms of the debt securities set forth in the applicable prospectus
supplement, holders of the debt securities may present the debt securities
for
exchange or for registration of transfer, duly endorsed or with the form of
transfer endorsed thereon duly executed if so required by us or the security
registrar, at the office of the security registrar or at the office of any
transfer agent designated by us for this purpose. Unless otherwise provided
in
the debt securities that the holder presents for transfer or exchange, we will
impose no service charge for any registration of transfer or exchange, but
we
may require payment of any taxes or other governmental charges.
We
will
name in the applicable prospectus supplement the security registrar, and any
transfer agent in addition to the security registrar, that we initially
designate for any debt securities. We may at any time designate additional
transfer agents or rescind the designation of any transfer agent or approve
a
change in the office through which any transfer agent acts, except that we
will
be required to maintain a transfer agent in each place of payment for the debt
securities of each series.
If
we
elect to redeem the debt securities of any series, we will not be required
to:
·
|
issue,
register the transfer of, or exchange any debt securities of that
series
during a period beginning at the opening of business 15 days before
the
day of mailing of a notice of redemption of any debt securities that
may
be selected for redemption and ending at the close of business on
the day
of the mailing; or
|
·
|
register
the transfer of or exchange any debt securities so selected for
redemption, in whole or in part, except the unredeemed portion of
any debt
securities we are redeeming in
part.
|
Information
Concerning the Debt Securities Agent
The
debt
securities agent, if any, other than during the occurrence and continuance
of an
event of default under the debt securities, may undertake to perform only those
duties as are specifically set forth in the applicable documentation for such
debt securities. Upon an event of default under the debt securities, the debt
securities agent must use the same degree of care as a prudent person would
exercise or use in the conduct of his or her own affairs. Subject to this
provision, the debt securities agent is under no obligation to exercise any
of
the powers given it by the debt securities at the request of any holder of
debt
securities unless it is offered reasonable security and indemnity against the
costs, expenses and liabilities that it might incur.
Payment
and Paying Agents
Unless
we
otherwise indicate in the applicable prospectus supplement, we will make payment
of the interest on any debt securities on any interest payment date to the
person in whose name the debt securities, or one or more predecessor securities,
are registered at the close of business on the regular record date for the
interest.
We
will
pay principal of and any premium and interest on the debt securities of a
particular series at the office of the paying agents designated by us, except
that unless we otherwise indicate in the applicable prospectus supplement,
we
will make interest payments by check that we will mail to the holder or by
wire
transfer to certain holders. We will name in the applicable prospectus
supplement any paying agents that we initially designate for the debt securities
of a particular series.
All
money
we pay to a paying agent or the debt securities agent for the payment of the
principal of or any premium or interest on any debt securities that remains
unclaimed at the end of two years after such principal, premium or interest
has
become due and payable will be repaid to us, and the holder of the debt security
thereafter may look only to us for payment thereof.
Governing
Law
The
debt
securities will be governed by and construed in accordance with the laws of
the
State of New York.
PLAN
OF DISTRIBUTION
We
may
sell the securities covered by this prospectus from time to time. Registration
of our securities covered by this prospectus does not mean, however, that those
securities will necessarily be offered or sold.
We
may
sell the securities through one or more underwriters or dealers in a public
offering and sale by them, through agents and/or directly to one or more
investors. We may sell the securities from time to time in one or more
transactions at a fixed price or prices, which may be changed from time to
time,
at market prices prevailing at the times of sale, at prices related to such
prevailing market prices, or at negotiated prices. For each offering of
securities hereunder, we will describe the method of distribution of such
securities in a prospectus supplement. The prospectus supplements will describe
the terms of the offerings of the securities, including:
·
|
The
name or names of any underwriters, if
any;
|
·
|
The
purchase price of our securities and the proceeds we will receive
from the
sale;
|
·
|
Any
overallotment options under which underwriters may purchase additional
securities from us;
|
·
|
Any
agency fees or underwriting discounts and other items constituting
agents’
or underwriters’ compensation;
|
·
|
Any
public offering price;
|
·
|
Any
discounts or concessions allowed or reallowed or paid to dealers;
and
|
·
|
Any
securities exchange or market on which our common stock or other
securities may be listed.
|
Only
underwriters named in the prospectus supplement are underwriters of the
securities offered by that prospectus supplement.
If
underwriters are used in the sale, they will acquire the securities for their
own account and may resell the securities from time to time in one or more
transactions at a fixed public offering price. The obligations of the
underwriters to purchase the securities will be subject to the conditions set
forth in the applicable underwriting agreement. We may offer the securities
to
the public through underwriting syndicates represented by managing underwriters
or by underwriters without a syndicate. Subject to certain conditions, the
underwriters may be obligated to purchase all the securities offered by the
prospectus supplement. Any public offering price and any discounts or
concessions allowed or reallowed or paid to dealers may change from time to
time. We may use underwriters with whom we have a material relationship. We
will
describe in the prospectus supplement, naming the underwriter, the nature of
any
such relationship. We may sell securities directly or through agents we
designate from time to time. We will name any agent involved in the offering
and
sale of securities and we will describe any commissions we will pay the agent
in
the prospectus supplement. Unless the prospectus supplement states otherwise,
any such agent will act on a best-efforts basis for the period of its
appointment.
We
may
authorize agents or underwriters to solicit offers by certain types of
institutional investors to purchase securities from us at the public offering
price set forth in the prospectus supplement pursuant to delayed delivery
contracts providing for payment and delivery on a specified date in the future.
We will describe the conditions to these contracts and the commissions we must
pay for solicitation of these contracts in the prospectus
supplement.
We
may
provide underwriters and agents with indemnification against civil liabilities
related to this offering, including liabilities under the Securities Act of
1933, as amended, or Securities Act, or contribution with respect to payments
that the underwriters or agents may make with respect to such
liabilities.
All
securities we offer, other than common stock, will be new issues of securities
with no established trading market. Any underwriters may make a market in
these securities, but will not be obligated to do so and may discontinue any
market making at any time without notice. We cannot guarantee the
liquidity of the trading markets for any securities.
Any
underwriter may engage in overallotment, stabilizing transactions, short
covering transactions and penalty bids in accordance with Regulation M under
the
Securities Exchange Act of 1934, as amended, or Exchange Act. Overallotment
involves sales in excess of the offering size, which create a short position.
Stabilizing transactions permit bids to purchase the underlying security so
long
as the stabilizing bids do not exceed a specified maximum. Short covering
transactions involve purchase of the securities in the open market after the
distribution is completed to cover short positions. Penalty bids permit the
underwriters to reclaim a selling concession from a dealer when the securities
originally sold by the dealer is purchased in a covering transaction to cover
short positions. Those activities may cause the price of the securities to
be
higher than it would otherwise be. If commenced, the underwriters may
discontinue any of these activities at any time.
Any
underwriters who are qualified market makers on the NASDAQ Capital Market may
engage in passive market making transactions in our common stock on the NASDAQ
Capital Market in accordance with Rule 103 of Regulation M, during the business
day prior to the pricing of the offering, before the commencement of offers
or
sales of common stock. Passive market makers must comply with applicable volume
and price limitations and must be identified as passive market makers. In
general, a passive market maker must display its bid at a price not in excess
of
the highest independent bid for such security; if all independent bids are
lowered below the passive market maker’s bid, however, the passive market
maker’s bid must then be lowered when certain purchase limits are
exceeded.
We
make
no representation or prediction as to the direction or magnitude of any effect
that any of the foregoing activities may have on the price of our common stock
or, if applicable, the price for any of our other securities. For a description
of these activities, see the information under the heading “Underwriting” or
“Plan of Distribution” in the applicable prospectus supplement.
Underwriters,
broker-dealers or agents who may become involved in the sale of our securities
may engage in transactions with and perform other services for us in the
ordinary course of their business for which they receive compensation.
LEGAL
MATTERS
The
validity of the securities being offered by this prospectus will be passed
upon
for us by Blank Rome LLP, New York, New York and for any underwriters, dealers
or agents by counsel named in the applicable prospectus supplement.
EXPERTS
The
financial statements as of December 31, 2007 and for each of the two years
in
the period ended December 31, 2007 incorporated by reference herein have been
so
incorporated in reliance on the report of BDO Seidman, LLP, an independent
registered public accounting firm, incorporated herein by reference, given
on
the authority of said firm as experts in auditing and accounting.
WHERE
YOU CAN FIND MORE INFORMATION
We
are
subject to the informational requirements of the Exchange Act, and we file
reports and other information with the SEC.
You
may
read and copy any of the reports, statements, or other information we file
with
the SEC at its Public Reference Section at 100 F Street, N.E., Room 1580,
Washington, D.C. 20549 at prescribed rates. Information on the operation of
the
Public Reference Room may be obtained by calling the SEC at 1-800-SEC-0330.
The
SEC also maintains a Web site at http://www.sec.gov that contains reports,
proxy
statements and other information regarding issuers that file electronically
with
the SEC. In addition, the Nasdaq Stock Market maintains a Web site at
http://www.nasdaq.com that contains reports, proxy statements and other
information filed by us.
Our
internet address is www.hudsontech.com.
We
make
available free of charge, on or through our web site, annual reports on form
10-KSB and 10-K,
quarterly reports on form 10-Q, current reports on Form 8-K and amendments
to
those reports filed or furnished pursuant to Section 13(a) or 15(d) of the
Exchange Act as soon as reasonably practicable after we electronically file
such
material with, or furnish it to, the SEC. Information contained on our web
site
is not part of this prospectus.
This
prospectus constitutes a part of a registration statement on Form S-3 that
we
have filed with the SEC under the Securities Act. This prospectus does not
contain all of the information set forth in the registration statement, certain
parts of which are omitted in accordance with the rules and regulations of
the
SEC. For further information about us and our securities we refer you to the
registration statement and the accompanying exhibits and schedules. The
registration statement may be inspected at the Public Reference Room maintained
by the SEC at the address set forth in the first paragraph of this section.
Statements contained in this prospectus regarding the contents of any contract
or any other document filed as an exhibit are not necessarily complete. In
each
instance, reference is made to the copy of such contract or document filed
as an
exhibit to the registration statement, and each statement is qualified in all
respects by that reference.
INFORMATION
INCORPORATED BY REFERENCE
The
SEC
allows us to “incorporate by reference” into this prospectus the information we
file with them. This means that we may disclose important information to you
by
referring you to other documents filed separately with the SEC. The information
we incorporate by reference into this prospectus is legally deemed to be a
part
of this prospectus, except for any information superseded by other information
contained in, or incorporated by reference into, this prospectus. Any
statement contained in a document incorporated or deemed to be incorporated
by
reference into this prospectus will be deemed to be modified or superseded
for
purposes of this prospectus to the extent that a statement contained in this
prospectus or any other subsequently filed document that is deemed to be
incorporated by reference into this prospectus modifies or supersedes the
statement. Any statement so modified or superseded will not be deemed, except
as
so modified or superseded, to constitute a part of this prospectus. Our SEC
File
Number for documents we filed under the Securities Exchange Act of 1934 is
001-13412.
The
following documents filed by us with the SEC are hereby incorporated by
reference in this prospectus:
·
|
our
annual report on Form 10-KSB (including the information incorporated
by
reference therein) for the fiscal year ended December 31,
2007;
|
·
|
our
quarterly report on Form 10-Q for the quarter ended March 31, 2008;
|
·
|
our
quarterly report on Form 10-Q for the quarter ended June 30, 2008;
|
·
|
our
current reports on Form 8-K filed with the SEC on January 11, 2008,
April 22, 2008, May 27, 2008 and September 2,
2008;
|
·
|
the
description of our common stock contained in our registration statement
on
Form 8-A, filed with the SEC pursuant to Section 12(g) of the
Exchange Act and all amendments or reports filed by us for the purpose
of
updating those descriptions.
|
All
reports and other documents subsequently filed by us pursuant to Sections 13(a),
13(c), 14 and 15(d) of the Exchange Act after the date of this prospectus and
prior to the termination of this offering also shall be deemed to be
incorporated by reference in this prospectus and to be part hereof from the
dates of filing of such reports and other documents; provided, however, that
we
are not incorporating any information furnished under either Item 2.02 or
Item 7.01 of any Current Report on Form 8-K.
We
hereby
undertake to provide without charge to each person, including any beneficial
owner, to whom a copy of this prospectus is delivered, upon written or oral
request of any such person, a copy of any and all of the information that has
been or may be incorporated by reference in this prospectus, other than exhibits
to such documents, unless the exhibits are specifically incorporated by
reference into the documents that this prospectus incorporates. Requests for
such copies should be directed to our corporate secretary, at the following
address or by calling the following telephone number:
Hudson
Technologies, Inc.
P.O.
Box
1541
One
Blue
Hill Plaza
Pearl
River, NY 10965
Telephone:
(845) 735-6000